The prior article in the two-part series challenged the traditional view of economics as merely the management of scarce ...

Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients ...

The fast-food chain argues in a counterclaim against Paradigm Investment Group that the operator is the only traditional ...

When a retailer offers a chatbot to communicate with customers and solve their queries, or when a bank sends an SMS for ...

Even though attendance in the office is crawling up, that growth is slowing, and the entire paradigm of how companies use ...

Investing.com -- Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) fell 1.2% following the U.S. Food and Drug Administration’s (FDA) Refusal to File (RTF) letter regarding the company’s New Drug ...

Axsome Therapeutics (AXSM) shares drop after FDA declines review of fibromyalgia treatment AXS-14. Read more here.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ('Formosa', 6838.TW), today announced a licensing agreement, whereby Harrow has ...

Bitcoin’s success reflects a growing shift in how the world approaches not only cryptocurrency but also financial markets as ...

Axsome Therapeutics received a refusal-to-file letter from the Food and Drug Administration for its new drug application for its fibromyalgia drug AXS-14.

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia ...